KOL | Hugh John WillisonInstitute of Infection, Immunity and Inflammation (3I), University of Glasgow, Glasgow, United Kingdom | Institute of Infection, Immunity and Inflammation, College of Medical, ... |
KOL Resume for Hugh John Willison
| Year | |
|---|---|
| 2022 | Institute of Infection, Immunity and Inflammation (3I), University of Glasgow, Glasgow, United Kingdom |
| 2021 | Institute of Infection, Immunity & Inflammation, University of Glasgow, University Place, Glasgow, UK |
| 2020 | Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK |
| 2019 | Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, 120 University Place, Glasgow, UK |
| 2018 | Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland. Electronic address: |
| 2017 | Department of Neuroimmunology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK Glasgow, United Kingdom |
| 2016 | Hugh J. Willison is at the Institute of Infection, Immunity and Inflammation, University of Glasgow, University Place, Glasgow, G12 8TA, Scotland, UK. Unit of Emerging Infectious Diseases, Institut Louis Malardé, Papeete, Tahiti, French Polynesia (V.-M.C.-L., C.R., A.T., D.M.); Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France (A.B., T.D., A.F.); Service de Réanimation Polyvalente (S.M., L.B.) and Clinical Laboratory (S.L.), Centre Hospitalier de Polynésie Française, Tahiti, French Polynesia; Institut Pasteur, Laboratory for Urgent Responses to Biological Threats (J.V., J.-C.M.); Unit Environment and Infectious Risks, Institut Pasteur (J.V., V.C., J.-C.M.), Paris, France; Service de Neurologie, Centre Hospitalier de Polynésie Française, Papeete, Tahiti (P.L., F.G.); Direction de la Santé, Bureau de Veille Sanitaire, Papeete (A.-L.V., H.-P.M.); Service de Santé des Forces Armées, Papeete (C.D.), French Polynesia; Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (S.K.H., H.J.W.); Department of Immunology, Laboratory of Immunochemistry & Autoimmunity, Pitié-Salpêtrière Hospital (AP-HP), Paris (L.M.); University of Reunion Island, La Reunion (P.D.); Département de Neurophysiologie, Pitié-Salpêtrière Hospital (AP-HP), Paris (E.F.); Conservatoire National des Arts et Métiers, Paris (A.F.); and Institut Pasteur, Centre for Global Health Research and Education, Paris (A.F.), France Neuroimmunology Group, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK |
| 2015 | Institute of Infection, Immunity and Inflammation College of Medical Veterinary and Life Sciences, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, G12 8TA |
| 2014 | From the College of Medicine (H.W.), Veterinary Medicine and Life Sciences, University of Glasgow, UK; and Department of Neurology (S.S.S.), The Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Glasgow Biomedical Research Centre, College of Medical, Veterinary and Life Science, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK. |
| 2013 | University of Glasgow Institute of Infection, Immunity and Inflammation College of Medical, Veterinary and Life Sciences Glasgow UK |
| 2012 | From MRC Center for Neuromuscular Disease (R.A.C.H.), National Hospital for Neurology and Neurosurgery, Queen Square, London; and Institute of Infection, Immunity and Inflammation (H.J.W.), Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, UK. Medical College of Georgia, USA Institute of Immunology, Immunity and Infection, University of Glasgow, Glasgow, G12 8TA, UK |
| 2011 | University of Glasgow College of Medical, Veterinary and Life Sciences, Glasgow Biomedical Research Centre, Room B330, 120 University Place, G12 8TA, Glasgow, UK Department of Neurology |
| 2010 | 1 Division of Clinical Neurosciences, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow G12 8TA, UK Division of Clinical Neuroscience, University of Glasgow, Glasgow, Scotland |
| 2009 | Divison of Clinical Neurosciences, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow G12 8TA, UK Division of Clinical Neurosciences, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom., Department of Neurology and, Department of Molecular Cell Biology — Group Neurophysiology, Leiden University Medical Centre, Leiden, The Netherlands., Henry Wellcome Laboratory of Cell Biology, Division of Biochemistry and Molecular Biology, Faculty of Biomedical and Life Sciences, University of Glasgow, Glasgow, United Kingdom., Department of Biochemistry II, Nagoya University School of Medicine, Nagoya, Japan. |
| 2008 | Neuroimmunology Laboratory, Division of Clinical Neurosciences, University of Glasgow, Glasgow, UK Division of Clinical Neurosciences, Glasgow Biomedical Research Centre, University of Glasgow, Scotland G12 8TA, United Kingdom |
| 2007 | Division of Clinical Neurosciences, University of Glasgow, Scotland |
| 2006 | Division of Clinical Neurosciences, University of Glasgow, Southern General Hospital, Glasgow G51 4TF, United Kingdom |
| 2005 | University Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, Scotland Head of the Peripheral Neuropathy Research Center and Consultant in Neurology, Mayo Clinic, Rochester, Minnesota Professor of Neurology and Roy E. and Merle Meyer Professor of Neuroscience, Mayo Clinic College of Medicine |
Hugh John Willison: Influence Statistics
| Concept | World rank |
|---|---|
| antigq1bpositive serum samples | #1 |
| membrane microdomains sulfatides | #1 |
| hexoses antiganglioside antibodies | #1 |
| human antiganglioside | #1 |
| sgpg antigens | #1 |
| human igm paraproteins | #1 |
| lipopolysaccharides guillain barré | #1 |
| animal gangliosides humans | #1 |
| neuropathy‐related | #1 |
| antibody reactivity complexes | #1 |
| gangliosides myelin proteins | #1 |
| target glycan structures | #1 |
| 11 ratio gm1 | #1 |
| notable pathogenic | #1 |
| cohort studies gbs | #1 |
| gm1like saccharides | #1 |
| animal gm1 humans | #1 |
| myelination neurite density | #1 |
| desheathed nerve nodes | #1 |
| clinical outcome gbs | #1 |
| antigq1b antibody alphaltx | #1 |
| cold agglutinating activity | #1 |
| cst galnac | #1 |
| lactontetraose igg | #1 |
| jack griffin colleagues | #1 |
| uninjured myelinating cultures | #1 |
| syndromes gbs | #1 |
| gbs goodfellow | #1 |
| c5 inhibitor rev576 | #1 |
| lps jejuni gm1 | #1 |
| 17 25 mgus | #1 |
| nerve terminal debris | #1 |
| electrophysiology gangliosides | #1 |
| demyelinating electrophysiology | #1 |
| bystander axonal | #1 |
| antigq1b antibodies | #1 |
| gm1 ganglioside neurons | #1 |
| human paralytic neuropathy | #1 |
| glial complex gangliosides | #1 |
| normal antibody sera | #1 |
| myelination neurite extension | #1 |
| presynaptic neuronal membranes | #1 |
| subacute injury model | #1 |
| injury psc | #1 |
| specific neuronal roles | #1 |
| ranvier role | #1 |
| elisa glycoarray | #1 |
| alphaltx effects | #1 |
| 80 igm monoclonal | #1 |
| nmj block | #1 |
Open the FULL List in Excel | |
Prominent publications by Hugh John Willison
Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study
[ PUBLICATION ]
BACKGROUND: Between October, 2013, and April, 2014, French Polynesia experienced the largest Zika virus outbreak ever described at that time. During the same period, an increase in Guillain-Barré syndrome was reported, suggesting a possible association between Zika virus and Guillain-Barré syndrome. We aimed to assess the role of Zika virus and dengue virus infection in developing Guillain-Barré syndrome.
METHODS: In this case-control study, cases were patients with Guillain-Barré ...
| Known for Zika Virus | Barré Syndrome | French Polynesia | Patients Guillain | Neurological Symptoms |
Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia
[ PUBLICATION ]
Densitometry of immunostained Western blots or thin layer chromatograms and enzyme-linked immunosorbent assays (ELISAs) were used to compare the relative strengths of IgM binding to myelin-associated glycoprotein (MAG), P0 glycoprotein, peripheral myelin protein-22 (PMP-22), sulfate-3-glucuronyl paragloboside (SGPG), and other potential target antigens in a series of eleven patients with sensory or sensorimotor demyelinating neuropathy and IgM paraproteinemia. The IgM from all patients ...
| Known for Mag Sgpg | Igm Paraproteinemia | Immunoglobulin Immunoglobulins | Demyelinating Neuropathy | Myelin Glycoprotein |
The species distribution of nervous system antigens that react with anti-myelin-associated glycoprotein antibodies
[ PUBLICATION ]
The reactivity of monoclonal and polyclonal antibodies directed against human central nervous system (CNS) myelin-associated glycoprotein (MAG) was investigated in a number of animal species. The antibodies included mouse monoclonal antibodies obtained by immunization with human MAG; HNK-1, a mouse monoclonal antibody raised against a human lymphoblastoma and used to identify a subset of lymphocytes with natural killer function; human IgM paraproteins associated with neuropathy; and ...
| Known for Species Distribution | Human Mag | Glycoprotein Antibodies | Molecular Weight | Mouse Monoclonal |
The neurophysiological effects of nine neuropathy-associated human anti-ganglioside antisera, three monoclonal antibodies to ganglioside GM1 (GM1) and of the cholera toxin B subunit (a GM1 ligand) were studied on mouse sciatic nerve in vitro. GM1 antisera and monoclonal antibodies from patients with chronic motor neuropathies and Guillain-Barre syndrome, and GQ1b/ disialosyl antisera and monoclonal antibodies from patients with chronic ataxic neuropathies and Miller Fisher syndrome were ...
| Known for Ganglioside Antibodies | Conduction Block | Nodes Ranvier | Sciatic Nerve | Miller Fisher Syndrome |
Guillain-Barré Syndrome-Related Campylobacter jejuni in Bangladesh: Ganglioside Mimicry and Cross-Reactive Antibodies
[ PUBLICATION ]
BACKGROUND: Campylobacter jejuni is the predominant antecedent infection in Guillain-Barré syndrome (GBS). Molecular mimicry and cross-reactive immune responses to C. jejuni lipo-oligosaccharides (LOS) precipitate the development of GBS, although this mechanism has not been established in patients from developing countries. We determined the carbohydrate mimicry between C. jejuni LOS and gangliosides, and the cross-reactive antibody response in patients with GBS in ...
| Known for Campylobacter Jejuni | Patients Gbs | Reactive Antibodies | Barré Syndrome | Developing Countries |
Guillain-Barré syndrome following Campylobacter jejuni infection is frequently associated with anti-ganglioside autoantibodies mediated by molecular mimicry with ganglioside-like oligosaccharides on bacterial lipopolysaccharide (LPS). The regulation of antibody responses to these T-cell-independent antigens is poorly understood, and only a minority of Campylobacter-infected individuals develop anti-ganglioside antibodies. This study investigates the response to gangliosides and LPS in ...
| Known for Campylobacter Jejuni | Inbred Balb Mice | Antibody Responses | Complex Gangliosides | Barré Syndrome |
Siglec-7 is a CD33-related sialic acid-binding Ig-like lectin expressed strongly on NK cells, where it can function as an inhibitory receptor. Its sialic acid-binding activity on NK cells is masked by cis interactions with sialylated glycans, which are likely to be important for regulating the inhibitory function of Siglec-7, which exhibits an unusual preference for alpha2,8-linked disialic acids, a motif found in "b-series" gangliosides and some glycoproteins. To investigate the ...
| Known for Nk Cells | Inhibitory Receptor | Natural Killer | Cis Interactions | Sialic Acids |
Anti-disialoside antibodies (Abs) that bind NeuAc(alpha2-8) NeuAc epitopes on GQ1b and related gangliosides are found in human autoimmune neuropathy sera and are considered to be pathogenic. In a model system in mice, one mechanism by which anti-disialoside Abs have been demonstrated to induce paralysis is through a complement dependent blocking effect on transmitter release at the neuromuscular junction, similar to the effects of alpha-latrotoxin. Although direct targeting of ...
| Known for Membrane Attack Complex | Schwann Cells | Nerve Terminal | Inbred Balb Mice | Murine Model |
BACKGROUND: Guillain-Barré syndrome (GBS) is an acute, immune-mediated flaccid paralysis frequently associated with Campylobacter infection. Of two predominant GBS subtypes, a demyelinating subtype (acute inflammatory demyelinative polyneuropathy [AIDP]) predominates in the United States and Europe, and axonal subtype (acute motor axonal neuropathy [AMAN]) is the predominant form in China. Previous clinical studies suggested that AMAN also occurs in Mexican children. The purpose of this ...
| Known for Aman Aidp | Barré Syndrome | Gbs Children | Campylobacter Infection | Acute Motor |
We investigated the possible mechanisms of paralysis and recovery in a patient with the acute motor axonal neuropathy (AMAN) pattern of the Guillain-Barré syndrome. The AMAN pattern of GBS is characterized clinically by acute paralysis without sensory involvement and electrodiagnostically by low compound motor action potential amplitudes, suggesting axonal damage, without evidence of demyelination. Many AMAN patients have serologic or culture evidence of recent Campylobacter jejuni ...
| Known for Motor Nerve | Campylobacter Infection | Axonal Neuropathy | Cases Aman | Rapid Recovery |
To determine whether antibodies to acidic glycolipids of nervous tissue are present in patients with Guillain-Barré syndrome (GBS), sera from patients with GBS and appropriate control subjects were tested by a thin-layer chromatogram overlay technique. Chromatograms on which the whole ganglioside fractions from peripheral nerve and brain had been separated were overlaid with appropriate dilutions of the patients' sera (1:100 or greater), and antibody binding was revealed with a ...
| Known for Patients Gbs | Antibodies Gangliosides | Clinical Improvement | Guillain‐barré Syndrome | Peripheral Nerve |
Anti-GD1a ganglioside antibodies (Abs) are the serological hallmark of the acute motor axonal form of the post-infectious paralysis, Guillain-Barre syndrome. Development of a disease model in mice has been impeded by the weak immunogenicity of gangliosides and the apparent resistance of GD1a-containing neural membranes to anti-GD1a antibody-mediated injury. Here we used mice with altered ganglioside biosynthesis to generate such a model at motor nerve terminals. First, we bypassed ...
| Known for Motor Nerve | Gd1a Antibody | Mediated Injury | Campylobacter Jejuni | Inbred C57bl Mice |
Anti-GQ1b ganglioside antibodies are the serological hallmark of the Miller Fisher syndrome (MFS) variant of the paralytic neuropathy, Guillain-Barré syndrome, and are believed to be the principal pathogenic mediators of the disease. In support of this, we previously showed in an in vitro mouse model of MFS that anti-GQ1b antibodies were able to bind and disrupt presynaptic motor nerve terminals at the neuromuscular junction (NMJ) as one of their target sites, thereby causing muscle ...
| Known for Monoclonal Antibodies | Mediated Neuropathy | Ganglioside Antibody | Neuromuscular Junction | Complement Activation |
Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: a prospective observational study
[ PUBLICATION ]
BACKGROUND: Since 2015, the arthropod-borne viruses (arboviruses) Zika and chikungunya have spread across the Americas causing outbreaks, accompanied by increases in immune-mediated and infectious neurological disease. The spectrum of neurological manifestations linked to these viruses, and the importance of dual infection, are not known fully. We aimed to investigate whether neurological presentations differed according to the infecting arbovirus, and whether patients with dual ...
| Known for Northeast Brazil | Chikungunya Virus | Neurological Manifestations | Barré Syndrome | Nervous Diseases |
Cost–utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy
[ PUBLICATION ]
The aim of this study was to provide an incremental cost-effectiveness analysis comparing intravenous immunoglobulin (IVIg) and prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy. Patients were recruited to a double-blind randomized crossover trial from nine European centres and received either prednisolone or IVIg during the first 6-week treatment period on which the economic evaluation was based. A societal perspective was adopted in measuring service ...
| Known for Chronic Inflammatory | Intravenous Immunoglobulin | Quality Life | Economic Evaluation | Service Costs |
Key People For Barré Syndrome
Hugh John Willison:Expert Impact
Concepts for whichHugh John Willisonhas direct influence:Barré syndrome, Complex gangliosides, Guillainbarré syndrome, Miller fisher syndrome, Zika virus, Campylobacter jejuni, Fisher syndrome, Motor nerve.
Hugh John Willison:KOL impact
Concepts related to the work of other authors for whichfor which Hugh John Willison has influence:Zika virus, Barré syndrome, Chronic inflammatory, Campylobacter jejuni, Zikv infection, Multiple sclerosis, Intravenous immunoglobulin.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |